Cargando…
Tissue catabolism and donor-specific dexamethasone response in a human osteochondral model of post-traumatic osteoarthritis
BACKGROUND: Post-traumatic osteoarthritis (PTOA) does not currently have clinical prognostic biomarkers or disease-modifying drugs, though promising candidates such as dexamethasone (Dex) exist. Many challenges in studying and treating this disease stem from tissue interactions that complicate under...
Autores principales: | Black, Rebecca Mae, Flaman, Lisa L., Lindblom, Karin, Chubinskaya, Susan, Grodzinsky, Alan J., Önnerfjord, Patrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185927/ https://www.ncbi.nlm.nih.gov/pubmed/35689293 http://dx.doi.org/10.1186/s13075-022-02828-4 |
Ejemplares similares
-
Proteomic clustering reveals the kinetics of disease biomarkers in bovine and human models of post-traumatic osteoarthritis
por: Black, Rebecca Mae, et al.
Publicado: (2021) -
DEXAMETHASONE: CHONDROPROTECTIVE CORTICOSTEROID OR CATABOLIC KILLER?
por: Black, R., et al.
Publicado: (2019) -
Proteomic analysis reveals dexamethasone rescues matrix breakdown but not anabolic dysregulation in a cartilage injury model
por: Black, Rebecca Mae, et al.
Publicado: (2020) -
The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors
por: Kokebie, Rediet, et al.
Publicado: (2011) -
Inflammatory cytokines and mechanical injury induce post-traumatic osteoarthritis-like changes in a human cartilage-bone-synovium microphysiological system
por: Dwivedi, Garima, et al.
Publicado: (2022)